Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
2.990
-0.180 (-5.68%)
At close: Nov 20, 2024, 4:00 PM
3.050
+0.060 (2.01%)
After-hours: Nov 20, 2024, 5:03 PM EST
Prime Medicine Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 13.86, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 363.55% from the current stock price of 2.99.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 → $15 | Strong Buy | Maintains | $17 → $15 | +401.67% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +234.45% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +234.45% | Oct 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +234.45% | Oct 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +234.45% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
5.12M
Revenue Next Year
6.20M
from 5.12M
Increased by 21.23%
EPS This Year
-1.77
from -2.18
EPS Next Year
-1.44
from -1.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 37.6M | n/a | ||
| Avg | 5.1M | 6.2M | n/a | ||
| Low | 578,200 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 634.8% | - | ||
| Avg | - | 21.2% | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.20 | -0.68 | -0.62 | ||
| Avg | -1.77 | -1.44 | -1.47 | ||
| Low | -1.87 | -1.76 | -1.89 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.